Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of
type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in …

Epidemiological studies suggest associations between diabetes mellitus and some cancers.
The risk of a number of cancers appears to be increased in diabetes mellitus. On the other …

We report the discovery and translational therapeutic efficacy of a peptide with potent,
balanced co-agonism at both of the receptors for the incretin hormones glucagon-like …

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic
drugs that improve glycemic control and many other atherosclerosis-related parameters in …

Controversy exists regarding the potential regenerative influences of incretin therapy on
pancreatic β-cells versus possible adverse pancreatic proliferative effects. Examination of …

Importance Acute pancreatitis has significant morbidity and mortality. Previous studies have
raised the possibility that glucagonlike peptide 1 (GLP-1)–based therapies, including a GLP …

Abstract Glucagon-like peptide-1 (GLP-1), an incretin hormone, is released from intestinal L-
cells in response to nutrients. GLP-1 lowers blood glucose levels by stimulating insulin …

Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular
benefits, but the relationship between GLP-1RA and tumors is controversial. Recently …